Therapeutic Vaccine for HIV

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

May 10, 2013

Primary Completion Date

February 26, 2017

Study Completion Date

February 26, 2017

Conditions
HIVTherapeutic Vaccine
Interventions
BIOLOGICAL

rVSV

Attenuated recombinant vesicular stomatitis virus containing HIV-1 gag gene

BIOLOGICAL

IL-12 pDNA adjuvant

plasmid DNA containing human IL-12 gene

BIOLOGICAL

HIV-Mag pDNA

plasmid DNA vaccine containing genes encoding multiple HIV-1 proteins

DRUG

Placebo

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Auro Vaccines LLC

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01859325 - Therapeutic Vaccine for HIV | Biotech Hunter | Biotech Hunter